

VA Antibigram

1 January 2025 - 31 December 2025

		PERCENT SUSCEPTIBLE (%)									
		IV Penicillin	Ampicillin / Amoxicillin †	Cloxacillin ‡ Cefazolin / Cephalixin	Ceftriaxone	Doxycycline *	Macrolides (Azithromycin or Clarithromycin)	Clindamycin	Trimethoprim- Sulfamethoxazole	Fluoroquinolones §	Vancomycin
ALL GRAM POSITIVE ORGANISMS		N									
<i>Staphylococcus aureus</i> complex (all)	1743			71		94		76	84	81	100
methicillin-susceptible (MSSA)	1234			100		99		81	93	91	100
methicillin-resistant (MRSA)	509			0		81		66	62	59	100
<i>Staphylococcus lugdunensis</i>	171			91		100		89	99	97	100
<i>Staphylococcus epidermidis</i>	211			31		87		54	54	60	100
Other <i>Staphylococcus</i> spp **	131 [†]			53		93		67	91	80	100
Viridans group <i>Streptococcus</i>	234	85	85		99						100
<i>Streptococcus pneumoniae</i> (non-meningitis) #	102	100	100		100	33	50			99	
<i>Streptococcus pneumoniae</i> (meningitis) #	55 [‡]	75			100						100
<i>Streptococcus pyogenes</i> (GAS)	303	100	100	100	100			81		99	100
<i>Streptococcus agalactiae</i> (GBS)	126	100	100	100	100			50		95	100
<i>Enterococcus faecalis</i>	890		100			24				80	99
<i>Enterococcus faecium</i>	392		7			28					64
vancomycin-susceptible <i>E. faecium</i>	250		12			28					100
vancomycin-resistant <i>E. faecium</i>	142		0			27					0
		<100 isolates provide less reliable results, regional results (R) used if possible									

R : Regional data

†: Ampicillin predicts piperacillin and imipenem for enterococci.

‡: Cloxacillin predicts amoxicillin-clavulanate, piperacillin-tazobactam and carbapenems for staphylococci.

*: For enterococci, % S for doxycycline is based on urinary isolates only.

§: For staphylococci, % S is based on ciprofloxacin breakpoints; for streptococci including *S. pneumoniae*, % S is based on moxifloxacin breakpoints; for *Enterococcus faecalis*, % S is based on ciprofloxacin breakpoints for urinary isolates only.

** : Other *Staphylococcus* spp include staphylococci other than *S. aureus* complex, *S. lugdunensis* and *S. epidermidis*.

: *Streptococcus pneumoniae* (non-meningitis) includes all isolates regardless of body sites and interpreted with CLSI non-meningitis, while *Streptococcus pneumoniae* (meningitis) includes a subset of invasive isolates (e.g. blood, CFS or bone&joint) interpreted with the CLSI meningitis breakpoints.

VA Antibigram

1 January 2025 - 31 December 2025

		PERCENT SUSCEPTIBLE (%)														
≥ 85%	No data or not		Ampicillin / Amoxicillin	Amoxicillin-Clavulanate	Cefazolin (systemic) §	Ceftriaxone	Ceftazidime	Trimethoprim-Sulfamethoxazole	Ciprofloxacin	Gentamicin	Tobramycin	Piperacillin-Tazobactam ‡	Meropenem	Cefazolin / 1st and 2nd gen oral cephalosporins (urine) §	Nitrofurantoin (urine)	
71-84%																
< 70%																
ALL GRAM NEGATIVE ORGANISMS		N														
Escherichia coli		2222	48	80	†	79	83	73	61	89	88	94	100	75	96	
ICU E. coli		46	28	60	†	57	63	50	46	85	78	83	96	53	88	
Klebsiella pneumoniae		620	0	90	†	86	88	85	82	96	95	94	99	83	28	
ICU K. pneumoniae		35	0	83	†	77	82	83	77	91	88	89	94	100	25	
Klebsiella oxytoca		155	0	85	†	88	95	86	88	95	92	89	99		79	
Proteus mirabilis		263	71	94	†	95	100	75	80	90	89	100	100	90		
Citrobacter koseri		119 [†]	0	97	†	97	97	100	98	99	99	97	99		82	
Citrobacter freundii complex		141 [†]	0	0	0	64	65	89	86	92	91	69	95		94	
Enterobacter cloacae complex		265	0	0	0	66	69	85	88	98	93	71	97		43	
Klebsiella aerogenes (prev. Enterobacter)		149 [†]	0	0	0	72	76	96	92	99	99	76	99		7	
Morganella morganii		149 [†]	0	0	0	95	90	81	79	89	91	99	99			
Serratia marcescens		127	0	0	0	88	97	98	93	98	88	95	98			
Pseudomonas aeruginosa		596					93		84	Δ	61	91	91			
ICU P. aeruginosa		47					83		81	Δ	49	83	87			
Acinetobacter spp.		135					86	88	94	95	93		96			
		<100	Isolates provide less reliable results, regional results (R) used if possible													

R : Regional data

§ : **Cefazolin (systemic)** interpretative criteria are based on a dosage regimen of 2g IV q8 hours in adults, assuming a normal kidney function. **Cefazolin (urine)** predicts susceptibility to the first and second-generation oral cephalosporins when used for the treatment of uncomplicated UTIs due to *E. coli*, *K. pneumoniae* and *P. mirabilis*.

† : Cefazolin (systemic) antibiogram is not displayed for the 2025 reporting period due to technical issues that may underestimate susceptibility rates and limit data reliability.

‡ : % of susceptible isolates to **piperacillin-tazobactam** includes **Susceptible-Dose Dependent (SDD)** isolates. **SDD** interpretative criteria are based on a high dosage regimen of 4.5g IV q6 hours over 3 h or 4.5 g IV q 8 h over 4h in adults, assuming normal kidney function. % of SDD isolates to piperacillin-tazobactam were identified in a total of 2.1% (82/3957) of all Enterobacteriales at VA.

Δ : % *Pseudomonas aeruginosa* isolates to gentamicin not being reported due to removal of CLSI breakpoints in 2023.